Mind Medicine (MindMed) Inc MNMD

Alternate Symbol(s): N.MMED.WS | N.MMED.WA | N.MMED.WR | N.MMED

Healthcare

Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing products to treat brain health disorders. It is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM-120 and MM-402, the Company's product candidates. MM120, is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that it is developing for the treatment of generalized anxiety disorder (GAD). MM-120 is also being studied in a subperceptual repeat administration dosing regimen for the treatment of attention deficit hyperactivity disorder (ADHD). MM-402, also referred to as R(-)-MDMA, is the Company's form of the R-enantiomer of 3,4-methylenedioxymethampheta (MDMA), which the Company is developing for the treatment of autism spectrum disorder (ASD).

NDAQ:MNMD - Post by User

Mind Medicine (MindMed) Inc > Just heard about this stock . . .

<< Previous

Bullboard Posts

Next >>

Post by Canadaforoilon Dec 18, 2020 2:40am

501 Views

Post# 32137990

Just heard about this stock . . .

and was wondering how they can get listed on the NASDAQ with a share price under the $5 USD opening bid and no sales. They need to have two quarters of sales over $1M.

While I think it could take off, I don't see how it can get listed in the U.S. yet.

Any ideas or am I missing something?

<< Previous

Bullboard Posts

Next >>

Investors eye Australian gold mining projects amid promising developments